

April 13, 2024

Re: Charles Haworth, nomination for ECFS Board

Dear ECFS,

I am pleased to offer this letter of support regarding the nomination of Dr. Charles Haworth for the ECFS Board. I have known Dr. Haworth for many years now, having worked with him in the areas of cystic fibrosis, bronchiectasis, and non-tuberculous mycobacteria. Although these areas are often discussed as separate fields, they are intimately linked and his broad grasp in these conditions make him an excellent choice for a board member.

He has a long and robust research record with publications in high-tier journals, and importantly, some of these publications are guidelines for our communities as well as important studies in aerosolized antibiotics and novel treatments such as the DPP1 inhibitors. He has served many leadership roles for the ECFS, as well as for the UK Trust, European Respiratory Society, British Thoracic Society and the US Cystic Fibrosis Foundation. As such, I feel that he will bring considerable leadership skills as well as a broad, international view to the board.

I have always found him to be engaged, polite, well-spoken, and thoughtful in all of the meetings that I have shared with him. In summary, I feel that Dr. Haworth has consistently contributed to the world of CF in all areas including clinical, teaching, research and service, certainly at the international level. I believe that he would be a great addition to the ECFS Board and I fully support his nomination.

Sincerely,



Patrick A Flume, M.D.

The Powers-Huggins Endowed Chair for Cystic Fibrosis
Distinguished Professor of Medicine and Pediatrics
Director, MUSC Cystic Fibrosis Center
Associate Vice President for Clinical Research
Medical University of South Carolina
Editor-in-Chief, Journal of Cystic Fibrosis



Fóilseoir na Seirbhíse Sláinte
Health Service Executive



Cork University Hospital
Ospidéal Oileáil Chiorc

Dept of Respiratory Medicine
Cork University Hospital
Wilton
Cork
Ireland
Fax: 021-4922596
Tel: 021 4922327
b.plant@ucc.ie

24.04.2024

Letter of support for Dr Charles Haworth for Executive Board Membership ECFS 2024.

Dear ECFS members,

It is an honour and a privilege for me to write a letter of support for my CF consultant colleague, Dr Charles Haworth. Dr Haworth has put his name forward to be considered as a new Executive Board Member of the ECFS. Having known him for almost 20 years I would unreservedly support his application for this position. I believe he would be an immense addition to the Board for multiple reasons which I will outline below.

Clearly Dr. Haworth is a world leader in clinical Cystic Fibrosis. Along with being the director of the Adult Cystic Fibrosis Service at Papworth Hospital and a founding member of the UK Cystic Fibrosis medical association, he has demonstrated over almost two decades his continued enthusiastic participation in support of the ECFS society in multiple ways. He has co-chaired a number of guidelines for our society including in the areas of bone health and NTM. He remains a Principal Investigator within the ECFS clinical trials network. He has repeatedly and continually participated in the ECFS meetings as a keynote speaker and a chair of many sessions. He has also participated regularly in the scientific steering committee for the ECFS guiding the direction in which our annual scientific meeting moves on an ongoing basis. In addition to this, he is extensively published in all areas of cystic fibrosis and clearly is an international leader in the area of NTM infection and CF.

On a personal level I have worked with him on multiple projects. He was a key figure and leader in the CFMATTERS European funded framework 7 research consortium and his participation and wisdom throughout this collaboration was very evident to me (and all members of the consortium). In addition he has on multiple occasions helped our programme with everything from advice on the treatment of difficult cases (NTM usually) to participating in many of our local and national CF meetings and training courses. In all encounters he remains highly approachable, collaborative, enthusiastic and totally up-to-date on the key topics that are critical to our community moving forward. In short these skills that he demonstrates are crucial to enhance the workings of our Executive Board. Finally whilst in this letter of support I find myself referring to him by his professional title, clearly he remains Charlie, a true friend to so many of us in cystic fibrosis.

I genuinely would urge you all to support his application. I believe his addition to the Board would enhance it greatly. He would, in my opinion, be an individual who would truly represent all members of our society to the benefit of Cystic Fibrosis care for all across Europe.

Kindest,

Prof. Barry Plant, MD, FRCPI